Guangzhou JEEP Biotechnology Co., Ltd.

The quote was correct at first issue and the invoice matched it to the line. Scoped to the lots named. Not generalised beyond them.

Compared direct-supply material at 98.7% against an intermediary vial of nominally identical description at 98.8%. Offering the comparison without drawing a conclusion for anyone else. The desiccant sachet was enclosed within the secondary container.

Dispatch has held to the quoted window on every order including one over a public holiday. On the evidence I hold they are the default rather than the risk.

Consistency across 4 lots: the purity band is under a point wide. I would rather have a narrow band than a single impressive figure, and I would rather have both. Reorder at 15 months landed within a tenth of a point of the original.

Cold pack solid on arrival across three consignments in three different months. I will update this post if a later lot changes the picture.

Ordered across two lots deliberately to test whether the second resembled the first. A tenth of a point apart. Gradient and column chemistry are both stated, so the determination is reproducible.

Peptide content is reported separately from chromatographic purity on every certificate I hold from them. Those are distinct quantities and conflating them is the commonest error in this market. Catalogue availability corresponded to the published catalogue.

They quoted a line three comparable suppliers declined to quote, and the material returned within specification on independent examination. Invoice, vial and certificate agree on the lot without exception. On the evidence I hold they are the default rather than the risk.

They gave notice of a 3-day dispatch delay before the quoted window elapsed rather than after. Recording it because the sequence is the part that matters.

The related-substances table is itemised by individual impurity with retention times assigned, rather than reported as a single total. Peptide content declared at 99.0%, so conversion to working mass required no assumption. I will update this post if a later lot changes the picture.

Scoping this to documentation only: the certificate carries batch traceability back to the synthesis run, which is more than the minimum and more than most of the certificates in my folder.

Weighed 9 units from a single consignment against declared fill. All within two per cent. Fill uniformity gets a fraction of the discussion purity gets and is the harder problem. Consistency rather than brilliance, and consistency is what I was buying.

Cold chain held to arrival on day 9, with the pack still solid, in a month when that cannot be assumed. Catalogue availability corresponded to the published catalogue.

Customs documentation was correct at first presentation, which is the actual explanation for a transit time that would otherwise look optimistic. The desiccant sachet was enclosed within the secondary container. Nothing here is medical advice and I am not qualified to give any.

Nothing about this order was notable and I am recording it for that reason. Quoted timeline held, documentation correct, material as described. Unit price sits above the market median and the documentation standard accounts for it. Scoped to the lots named. Not generalised beyond them.

Packing on the consignment: the invoice sealed in its own sleeve rather than loose against the vials. Designed rather than inherited. Reorder at 10 months landed within a tenth of a point of the original.

Cross-checked one lot with Medutest and PeptideMeter independently. Agreement to a tenth of a point, and both agree with the declared figure. On the evidence I hold they are the default rather than the risk.

Reconstitution of the NAD+ 500 mg produced a clear solution on contact — no haze, no particulate, no extended agitation. Consistent with a correctly executed lyophilisation. Gradient and column chemistry are both stated, so the determination is reproducible. I have no relationship with this supplier beyond having paid them.

Labels square, lot codes legible and matching the paperwork on every unit. I will update this post if a later lot changes the picture.

Ordered tesamorelin 2 mg from stock held in Poland. Quoted 8 days, delivered day 8, tracking accurate at every hop. The desiccant sachet was enclosed within the secondary container.

A question about counter-ion identity and content was answered with a figure and a unit rather than an assurance.

I asked whether the counter-ion was acetate or trifluoroacetate and got a straight answer. Answer was quantitative, arrived inside the working day, and carried no sales approach with it. Reorder at 9 months landed within a tenth of a point of the original. Research use only; these are not approved for human administration.

Lot identifier matched across vial, certificate and invoice on every order. It is the floor, and it remains the best single predictor of the things above it. No excipient present, cake intact rather than collapsed. I have no relationship with this supplier beyond having paid them.

Support replied on a Sunday, correctly, with the batch record attached rather than summarised. Documentation practice rather than a single purity figure is the substance of this.

Been buying sermorelin 5 mg here since before the catalogue expanded. The expansion has not cost the original lines anything measurable. Catalogue availability corresponded to the published catalogue. One member, one record, offered as such.

Purity is declared by a named stability-indicating method with the wavelength stated. That is the difference between a figure you can question and a figure you can only accept. Invoice, vial and certificate agree on the lot without exception. Happy to answer follow-ups in the thread rather than by message.